Walk Softly And Carry A Big Stick-New Therapeutics For Disease Management

Eric E. Schmidt, O.D.

1 Steroids

- A. Durezol
 - a. What makes it different
 - i. Emulsion
 - ii. Penetration
 - iii. Efficacy
 - iv. Potency
 - b. Clinical Studies
 - i. Head to head vs Prednisolone acetate
 - 1. Anti-inflammatory activity
 - 2. Side Effect comparisons
 - a. 1OP response
 - b. PSC formation
 - c. Clinical Experience
 - i. Uveitis therapy
 - 1. Dosage indications
 - ii. Post-op treatment
 - 1. Dosage instructions
 - d. Clinical Indications
- B. Tobradex ST
 - a. What makes it different
 - b. Clinical Indications
- C. Lotemax gel
 - a. What makes it different
 - i. Gel instead of suspension
 - ii. Delivery system
 - iii. Increases contact time
 - iv. Increased Anti-inflammatory effect
 - b. Clinical Studies
 - c. Clinical experience
 - i. Head to head vs Lotemax suspension
 - ii. Compared with Pred Forte
 - d. Clinical indications
- II. Antibiotics
 - A. Moxeza
 - a. What makes it different

- i. Dosage
- ii. Penetration
- iii. Potency
- iv. Efficacy
- b. Clinical Indications
- c. Clinical Trials

B. Besivance

- a. What makes it different
 - i. "Chloro-fluoroquinolone"
 - ii. Dosage
 - iii. Viscosity
 - iv. Sustained release
 - v. MRSA indication
- b. Clinical studies
- c. Clinical indications
 - i. Conjunctivitis dosage
 - ii. Corneal ulcer dosage

III. Topical Anti-histamines

- A. Bepreve
 - a. What makes it different
 - i. Dosage
 - ii. CAC Challenge
 - iii. Side Effect Profile
 - iv. Efficacy
 - b. Clinical Experience

B. Lastacaft

- a. What makes it different
 - i. Dosage
 - ii. Safety Profile
 - iii. CAC Challenge
 - iv. Efficacy
- b. Clinical Experience

IV. Anti-Glaucoma Drops

- A. Lumigan 0.01%
 - a. Head-to-head trials
 - c. Clinical Research
 - d. Clinical Improvements
 - e. Safety Profile
 - f. Clinical Indications

B.Zioptan

- g. What It Is
- h. What It Isn't
- i. Clinical Studies
- j. Clinical Indications
- k. Clinical Experience

C. Rescula

- a. Docosanoid
- b. Mechanism of Action
- c. Head to head trials
- d. Clinical Research
- e. Monotherapy vs Adjunctive therapy
- f. Clinical Indications
- g. Clinical Experience what can we expect

D. Cosopt PF

- a. Ingredients
- b. Clinical Indications
- c. Clinical Studies
- d. Clinical Experience
- e. Why is it different?

E. Simbrinza

- a. Ingredients
- b. Clinical Indications
- c. Dosage
- d. Clinical Studies
- e. Clinical Experience

VI. Latisse

- A. What Do We Know
 - a. Indication
 - b. Efficacy
 - c. Safety Profile
 - d. Duration

B. Clinical Questions

- a. How long to use?
- b. Repeatability?
- c. How to best Apply?

VII. Zirgan

- A. Anti-viral
- B. Clinical Indications
- C. Dosage
- D. Head to head trials
- E. Clinical Experience

VII. Dry Eye Products

- A. Lacrisert
 - a. Indications
 - b. Clinical Research
 - c. Insertion Procedures
 - d. Clinical Experience
- B. FreshKote
 - a. Indications
 - b. Dosage
 - c. Clinical Experience
- C. Artificial Tears 2012